Replacement therapy in Addison’s disease

@article{Lvs2003ReplacementTI,
  title={Replacement therapy in Addison’s disease},
  author={Kristian L{\o}v{\aa}s and Eystein Sverre Husebye},
  journal={Expert Opinion on Pharmacotherapy},
  year={2003},
  volume={4},
  pages={2145 - 2149}
}
Addison’s disease or primary adrenal insufficiency is a rare disease, which is usually caused by autoimmune destruction of the adrenal cortex. The clinical picture is caused by deficiency of cortisol and aldosterone. These deficiencies are accompanied by adrenal androgen depletion of yet unknown significance. The current therapy is the replacement of glucocorticoids and mineralocorticoids, but the available drugs do not restore the normal diurnal variations in serum hormone levels. The clinical… 
Therapy of adrenal insufficiency: an update
TLDR
A novel dual-release formulation of hydrocortisone, recently approved by EMEA, represents an advancement in the optimization of the clinical management of patients with adrenal insufficiency.
Glucocorticoid Treatment and Quality of Life in Addison’s disease
TLDR
Mimicking the physiological cortisol rhythm with CSHI proved safe and provides a means for further improving replacement therapy in AD and provided a valid and reliable new tool for HRQoL evaluation in AD.
Androgen replacement therapy in women
TLDR
Current replacement options include transdermal testosterone or oral dehydroepiandrosterone treatment, both of which have been shown to result in significant improvements, in particular in libido and mood, while long-term effects on body composition, cardiovascular and cancer risk are less documented.
Can side effects of steroid treatments be minimized by the temporal aspects of delivery method?
TLDR
The physiology and evidence behind the importance of different patterns of glucocorticoid presentation on gene regulation, animal responses and clinical significance are discussed and compelling evidence for pulsatility being an important factor in hypothalamic pituitary adrenal axis regulation and tissue responses is discussed.
Autoimmune Addison's Disease as Part of the Autoimmune Polyglandular Syndrome Type 1: Historical Overview and Current Evidence
TLDR
A comprehensive review of the studies on APS1-associated AAD from initial case reports to the most recent scientific findings.
Sexuality and fertility in women with Addison's disease.
TLDR
Despite androgen depletion, females with Addison's disease do not report impaired sexuality and the fertility is reduced after the diagnosis is made; the reasons for this remain unknown.
Cortisol-dependent stress effects on cell distribution in healthy individuals and individuals suffering from chronic adrenal insufficiency
TLDR
Using CAI in humans as a model confirms cortisol's central involvement in post-stress lymphocyte migration from blood into immune-relevant body compartments and investigates whether psychosocial stress exposure may put CAI patients at an increased health risk due to attenuated immune responses to pathogens.
Restore the Balance : Side effects of dexamethasone in children with acute lymphoblastic leukemia
TLDR
The aim of this study was to reduce dexamethasone-induced cerebral side effects on mood, behavior, sleep, and cognition by an intervention with physiological doses of cortisol, and to study the positive predictive value of a novel in vivo diagnostic test (salivary very low dose dexamthasone suppression test) on dexamithasone side effects.
Diagnosis and management of Addison's disease: insights gained from a large South African cohort
TLDR
A low threshold is required for screening, intervention and follow-up of all patients for cardiovascular risk factors, given the atherogenic profile observed among Addison's disease sufferers in South Africa.
9β Polymorphism of the Glucocorticoid Receptor Gene Appears to Have Limited Impact in Patients with Addison’s Disease
TLDR
This study did not identify any associations between the 9β polymorphism and cardiovascular risk factors or hydrocortisone dose and determination of this polymorphism is therefore unlikely to be of clinical benefit in the management of patients with AD.
...
1
2
3
...

References

SHOWING 1-10 OF 45 REFERENCES
Effect of Glucocorticoid Replacement Therapy on Bone Mineral Density in Patients with Addison Disease
TLDR
Bone mineral density was measured in a large group of patients with Addison disease to determine the importance of the Cushing syndrome and pharmacologic administration of glucocorticoids in the development of osteoporosis.
Assessment of Corticosteroid Replacement Therapy in Adults with Adrenal Insufficiency
TLDR
There is not much hard evidence that excessive glucocorticoid replacement per se will lead to adverse effects such as osteoporosis, and there is no compelling need for using determinations of either UFC excretion or of the serum cortisol profile in the routine management of patients on replacement therapy.
Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass.
TLDR
The bone mineral density was normal in premenopausal female patients as well as in male patients, showing that replacement doses of cortisone acetate do not affect bone mass, and the small amounts of androgens secreted by the adrenal cortex have a role in the maintenance of bone mass in normal postmenopausal women.
Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial.
TLDR
Positive effects in males, independent of circulating testosterone levels, suggest that it may act directly on the central nervous system rather than by augmenting peripheral androgen biosynthesis, and suggest a role for DHEA replacement therapy in the treatment of Addison's disease.
Bone mineral density is reduced in female but not male subjects with Addison's disease.
TLDR
Women with Addison's disease have a greater than expected reduction in bone mineral density, and it is postulate that this may be related to loss of adrenal androgens.
PATTERNS OF PLASMA CORTISOL AND ACTH CONCENTRATIONS IN PATIENTS WITH ADDISON'S DISEASE TREATED WITH CONVENTIONAL CORTICOSTEROID REPLACEMENT
Plasma cortisol and adrenocorticotrophin hormone (ACTH) profiles were estimated in twelve patients with Addison's disease following randomized oral administration of either cortisone acetate (25 mg)
Bone density and turnover in Addison's disease: effect of glucocorticoid treatment.
TLDR
The results show that in patients with AD, after replacement with low doses of glucocorticoids there is no significative trabecular bone loss neither modifications in bone formation markers.
Glucocorticoid replacement therapy: are patients over treated and does it matter?
TLDR
The aims of this study were to assess adequacy of glucocorticoid replacement in hypoadrenal patients, to correlate serum cortisol levels (cortisol day curve) with 24‐hour urine free cortisol excretion and to assess the impact of glucOCorticoids dose optimization on markers of bone formation and bone resorption.
DHEA treatment: myth or reality?
TLDR
DHEA has considerable effects on mood, well-being and sexuality in patients with adrenal insufficiency, and also in those with mood disorders, however, subjects with a physiological, age-related decline in DHEA secretion show little benefit from D HEA administration.
Quality of life in patients with Addison's disease: effects of different cortisol replacement modes.
TLDR
Quality of life in Addison patients is mainly influenced by the mode of cortisol replacement therapy, and sum scores of all questionnaires were changed towards improvement compared to both once-daily regimens.
...
1
2
3
4
5
...